Abstract

Conmed will release its fourth-quarter 2025 results on January 28, 2026 Post Market; this preview outlines consensus expectations for revenue, margins, EPS, and segment dynamics, and evaluates majority institutional views and stock-price drivers heading into the print.

Market Forecast

Consensus and company-tracked projections for the current quarter indicate total revenue of $366.80 million, implying year-over-year growth of 7.56% in US dollars, with estimated EBIT of $60.84 million and estimated EPS of $1.32, a year-over-year increase of 10.03%. Forecast commentary implies stable to slightly improving profitability, though detailed gross margin and net margin forecasts are not disclosed. The core businesses are expected to benefit from solid procedure volumes and steady order flow, while pricing and mix remain the key watch items. The ordinary surgery segment is the most promising area near term, supported by scale and utilization; last quarter, ordinary surgery revenue was $199.73 million, while orthopedic surgery revenue was $138.19 million.

Last Quarter Review

For the third quarter of 2025, Conmed reported revenue of $337.93 million in US dollars, a gross profit margin of 56.08%, GAAP net profit attributable to the parent company of $2.86 million, a net profit margin of 0.85%, and adjusted EPS of $1.08, up 2.86% year over year. Quarter-on-quarter, GAAP net profit contracted by 86.65%, reflecting temporary cost and mix headwinds that offset steady procedure growth and above-consensus sales.

A notable highlight was that revenue exceeded the prior estimate by $3.17 million, with EBIT of $51.17 million also topping the forecast by $1.09 million, suggesting underlying operational resilience despite one-off pressures on GAAP profitability. By business line, ordinary surgery generated $199.73 million and orthopedic surgery delivered $138.19 million; both segments benefited from steady utilization trends, with ordinary surgery retaining a higher share of revenue; detailed year-over-year segment growth was not disclosed.

Current Quarter Outlook

Main business momentum: diversified procedure exposure supports top-line stability

Conmed’s ordinary surgery franchise remains the largest revenue contributor and a central driver of quarterly outcomes. Heading into the fourth quarter, procedure volumes in general and laparoscopic surgeries typically remain resilient, which supports throughput across the company’s core disposables and capital equipment placements. Stable customer demand and replacement cycles are likely to support sequential order consistency, while inventory positions at hospitals appear rational based on last quarter’s order cadence. Price discipline and product mix will be crucial levers: with disposables comprising a meaningful share of sales, slight improvements in mix toward higher-value consumables can enhance revenue efficiency even if unit growth moderates. The primary swing factor for the main business this quarter is whether utilization tailwinds persist across U.S. and international accounts, as any pockets of softer elective activity could weigh modestly on growth.

Most promising business line: ordinary surgery scale and mix advantages

The ordinary surgery segment, which generated $199.73 million last quarter, is positioned to deliver the strongest incremental contribution in the current quarter forecast period. The scale of the franchise provides leverage on distribution and service, which can sustain gross profit margin resilience even as the company invests in commercial coverage and pipeline transitions. With forecast company revenue growth of 7.56% year over year, ordinary surgery’s breadth across procedure categories should allow it to capture demand from steady inpatient and outpatient settings, including ambulatory surgical centers. The key watch item is product mix: greater adoption of premium single-use devices, energy platforms, and visualization accessories can lift gross profit margin marginally from last quarter’s 56.08%, whereas a heavier capital mix or discounts to drive placements could cap upside. If operating expenses remain tightly managed, EBIT of $60.84 million for the quarter would indicate that the segment’s contribution margin trends are tracking in line with expectations.

Stock-price sensitivities this quarter: GAAP-to-non-GAAP bridge, margins, and volume elasticity

Investors will likely focus on three variables that can influence share performance around the print. The first is the bridge from GAAP to adjusted results: last quarter’s GAAP net profit margin of 0.85%, despite an adjusted EPS delivery of $1.08, suggests non-recurring items or non-cash charges that pressured GAAP margins; clarity on the magnitude and recurrence of these items can re-anchor valuation multiples. The second is margin direction into year-end: with gross profit margin previously at 56.08%, the outlook for sequential and year-over-year gross margin progression will inform confidence in the $60.84 million EBIT estimate and the $1.32 EPS forecast. The third is volume elasticity in the company’s core procedure categories; sustained hospital and ASC throughput would support the projected 7.56% revenue growth, while any disruption from staffing, budget timing, or procurement pauses could present downside to the top line. The market will also parse commentary on pricing, supply chain normalization, and working-capital discipline given the quarter-on-quarter volatility in GAAP profitability.

Analyst Opinions

Across recent institutional commentaries, the majority stance is moderately bullish, with a larger share of analysts expecting Conmed to meet or slightly exceed the current quarter’s estimates for revenue of $366.80 million, EBIT of $60.84 million, and EPS of $1.32. Positive views emphasize resilient procedure volumes, incremental pricing benefits, and operational execution that previously delivered upside to revenue and EBIT versus forecasts. Representative favorable opinions highlight the company’s ability to manage cost inflation and maintain gross profit margin stability near the mid-50% range while gradually re-levering operating expenses, which underpins confidence in the year-over-year EPS growth of 10.03%. The bull case also notes that last quarter’s GAAP-to-non-GAAP gap appears idiosyncratic rather than structural, and that improved mix within ordinary surgery can offset potential softness elsewhere. The minority cautious views point to the need for greater visibility on segment-level growth rates and gross margin cadence, but these perspectives remain less prevalent than the constructive camp at present.